335,541 Shares in AtriCure, Inc. $ATRC Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 335,541 shares of the medical device company’s stock, valued at approximately $9,388,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure during the 2nd quarter valued at about $37,000. Smartleaf Asset Management LLC increased its position in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in shares of AtriCure in the second quarter worth approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure in the second quarter valued at approximately $43,000. Finally, Fifth Third Bancorp purchased a new stake in AtriCure in the first quarter valued at approximately $51,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Trading Down 1.0%

ATRC stock opened at $48.17 on Thursday. The company has a market capitalization of $2.45 billion, a PE ratio of 229.39 and a beta of 1.20. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.88. The company’s 50 day moving average price is $37.09 and its two-hundred day moving average price is $32.06. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider directly owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Karen Prange sold 3,564 shares of AtriCure stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,616 shares of company stock worth $2,149,994 over the last 90 days. Insiders own 4.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ATRC. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. UBS Group lowered their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.62.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.